TAIZHOU, China, Aug. 12, 2019
/PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC)
("China SXT" or the "Company"), a specialty pharmaceutical company
focusing on the research, development, manufacturing, marketing,
and sales of Traditional Chinese Medicine Pieces ("TCMPs"),
announced today that it has been issued a new Certificate of GMP
(Good Manufacturing Practice) for Pharmaceutical Products (the
"Certificate") by the Food and Drug Administration of Jiangsu Province, China ("FDA").
The FDA staff conducted its on-site examination in accordance
with government regulations. The Certificate of GMP became
effective on August 5, 2019 and is valid until August 4, 2024. In addition to renewing the
previous certificate for the Company's manufacturing of the Regular
TCMP, Fine TCMP, and Directly-Oral TCMP, this Certificate also
includes the Company's high-electron electron beam
sterilization method and new After-Soaking-Oral TCMP
classification. The Company believes the Certificate for such
method and classification would be the first in the TCMP industry
nationwide.
Mr. Feng Zhou, Chief Executive
Officer and Director of China SXT, commented, "The Certificate of
GMP is a testament to our TCMP standards of highest quality,
further cement our lead on research and development, and benefit
the marketing of our advanced TCMP products in the future."
About China SXT Pharmaceuticals, Inc.
Founded in 2005 and headquartered in Taizhou City, Jiangsu Province, China, China SXT Pharmaceuticals, Inc. is an
innovative pharmaceutical company focusing on the research,
development, manufacture, marketing and sales of traditional
Chinese medicine pieces, which is a type of Traditional Chinese
Medicine that has been processed to be ready for use. For more
information, please visit www.sxtchina.com.
Safe Harbor Statement
This press release contains forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. When the Company uses words such as
"may, "will, "intend," "should," "believe," "expect," "anticipate,"
"project," "estimate" or similar expressions that do not relate
solely to historical matters, it is making forward-looking
statements. Specifically, the Company's statements regarding the
closing of the proposed private placement are forward-looking
statements. Forward-looking statements are not guarantees of future
performance and involve risks and uncertainties that may cause the
actual results to differ materially from the Company's expectations
discussed in the forward-looking statements. These statements are
subject to uncertainties and risks including, but not limited to,
the following: the Company's goals and strategies; the Company's
future business development; product and service demand and
acceptance; changes in technology; the growth of the pharmaceutical
market, particularly the Traditional Chinese Medicine Pieces
("TCMPs") market, in China;
reputation and brand; the impact of competition and pricing;
government regulations; fluctuations in general economic and
business conditions in China and
the international markets the Company serves and assumptions
underlying or related to any of the foregoing and other risks
contained in reports filed by the Company with the Securities and
Exchange Commission. For these reasons, among others, investors are
cautioned not to place undue reliance upon any forward-looking
statements in this press release. Additional factors are discussed
in the Company's filings with the U.S. Securities and Exchange
Commission, which are available for review at www.sec.gov. The
Company undertakes no obligation to publicly revise these
forward - looking statements to reflect events or
circumstances that arise after the date hereof.
For more information, please contact:
At the Company:
Alex Shi, CFO
Email: alexyaoshi@qq.com
ICR, LLC
Rose Zu
Email: ir@sxtchina.com
Phone: +1-646-277-1287
View original
content:http://www.prnewswire.com/news-releases/china-sxt-pharmaceuticals-inc-receives-new-pharmaceutical-gmp-certificate-300899329.html
SOURCE China SXT Pharmaceuticals, Inc.